The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2021 | Biomarkers in sickle cell disease
David Rees, MA, MBBS, FRCP, FRCPath, FRCPCH, King’s College Hospital, London, UK, discusses using biomarkers to predict outcomes in sickle cell disease (SCD), and suggests particular treatments. Using SCD biomarkers such as transcranial Doppler velocity measurements can effectively predict the risk of stroke in children. Despite various studies using SCD biomarkers as evidence to reveal the pathology of SCD, Prof. Rees outlines the limits of SCD biomarkers as a prognostic tool. This interview took place at the 2021 British Society for Haematology Annual Scientific Meeting.
